Skip to main content
×
×
Home

Long-Term Cardiovascular Effects of Mixed Amphetamine Salts Extended Release in Adults With ADHD

  • Richard H. Weisler, Joseph Biederman, Thomas J. Spencer and Timothy E. Wilens
Abstract

Objective: To assess long-term cardiovascular effects of mixed amphetamine salts extended release (MAS XR) in adults with attention-deficit/hyperactivity disorder (ADHD) combined subtype.

Methods: 223 otherwise healthy adults (≥18 years of age) with ADHD combined subtype were exposed to ≤24 months of MAS XR (20–60 mg/day). Resting sitting diastolic blood pressure (DBP) and systolic blood pressur (SBP) and pulse were measured at baseline and weekly, then monthly during long-term treatment. Twelve-lead electrocardiograms were obtained at screening/baseline, weekly, then at 3-and 6-month intervals up to 24 months.

Findings: With MAS XR 20–60 mg/day, mean changes in DBP (1.3±9.2 mm Hg; P=.O42), SBP (2.3±12.5 mmHg; P=.OO6), and pulse (2.1±13.4 bpm; P=.019) were small and not clinically significant. A clinically insignificant increase in QTcB (corrected by Bazett's formula) interval (7.2 msec; P<.001) was observed at 24 months. No subject exhibited QTcB interval >480 msec (QTcF [corrected by Fridericia's formula] >454 msec). Seven subjects discontinued due to a car-diovascular adverse event (hypertension, n=5, palpitation/tachycardia, n=2); none of these events was reported as serious. Few subjects with normal baseline vital signs (using approved parameters at the time of study initiation) exhibited clinically significant abnormalities at end point; several subjects with borderline baseline values exhibited shifts to abnormal values during MAS XR therapy.

Conclusion: Cardiovascular effects of long-term MAS XR (≤60 mg/day) were minimal in otherwise healthy adults with ADHD. Nevertheless, vital signs should be monitored prior to and during treatment with any stimulant.

Copyright
Corresponding author
Please direct all correspondence to: Richard H. Weisler, MD, Duke University Medical Center and University of North Carolina at Chapel Hill, 700 Spring Forest Rd., Suite 125, Raleigh, NC 27609; Tel: 919-872-5900; Fax: 919-878-0942; E-mail: rweisler@aol.com.
References
Hide All
1. Rowland, AS, Lesesne, CA, Abramowitz, AJ. The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. Ment Retard Dev Disabil Res Rev. 2002;8:162–17O.
2. Wilens, TE, Faraone, SV, Biederman, J. Attention-deficit/hyperactivity disorder in adults. JAMA. 2004;292(5):619623.
3. Weiss, G, Hechtman, L, Milroy, T, Perlman, T. Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Adolesc Psychiatry. 1985;24(2):211220.
4. Kessler, RC. Prevalence of adult ADHD in the United States: results from the National Comorbidity Survey Replication (NCS). Presentation at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
5. Dulcan, M. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1997;36(suppl 10):85S121S.
6. Greenhill, LL, Pliszka, S, Dulcan, MK, et al. ; American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41(suppl 2):26S49S.
7. Spencer, T, Wilens, T, Biederman, J, Faraone, SV, Ablon, S, Lapey, K. A double-blind cross-over comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1995;52(6):434443.
8. Wilens, TE, Hammemess, PG, Biederman, J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2005;66(2):253259.
9. Spencer, T, Biederman, J, Wilens, T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2001;58(8):775782.
10. Weisler, RH, Biederman, J, Spencer, T, Wilens, TE, Chrisman, AK. Adderall XR dosed once daily in adult patients with ADHD. Presentation at: 156th American Psychiatric Association Annual Meeting; May 20, 2003; San Francisco, CA.
11. Findling, RL, Short, EJ, Manos, MJ. Short-term cardiovascular effects of methylphenidate and Adderall. J Am Acad Child Adolesc Psychiatry. 2001;40(5):525529.
12. Safer, DJ, Relative cardiovascular safety of psychostimulants used to treat attention-deficit hyperactivity disorder. J Child Adobe Psychopharmacol. 1992;2:279290.
13. Gutgesell, H, Atkins, D, Barst, R, et al. AHA Scientific Statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J Am Acad Child Adolesc Psychiatry. 1999;38(8): 10471050.
14. Lampe, FC, Whincup, PH, Wannamethee, SG, et al. The natural history of prevalent ischaemic heart disease in middle-aged men. Eur Heart J. 2000;21(13):1052–lO62.
15. Wilens, TE, Biederman, J, Lerner, M; Concerta Study Group. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study. J Clin Psychopharmacol. 2004;24(1):3641.
16. Tulloch, SJ, Zhang, Y, McLean, A, Wolf, KN. SLI381 (Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration. Pharmacotherapy. 2002;22(11):14051415.
17. McCracken, JT, Biederman, J, Greenhill, LL, et al. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2003;42(6):673683.
18. Diagnostic and Statistical Manual for Mental Disorders. 4th ed text rev. Washington, DC: American Psychiatric Association; 2000.
19. DuPaul, G, Power, T, Anastopoulos, A, Ried, R. ADHD Rating Scale, IV: Checklists, Norms, and Clinical Interpretation. New York, NY: Guilford Press; 1998.
20. Bazett, H. An analysis of time relations of electrocardiogram. Heart. 1920;7:353370.
21. Chobanian, AV, Bakris, GL, Black, HR, et al. ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6): 12061252.
22. Chronic Disease Management. Government of British Columbia, Ministry of Health Services. May 2003. Available at: http://www.healthservices.gov. Accessed November 22, 2005.
23. Wilens, TE, Spencer, T, Biederman, J. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in adolescents. CNS Spectr. 2005;10(10 suppl 15):2230.
24. Wilens, TE, Biederman, J, Podolski, A, et al. Amphetamine treatment of ADHD in adults with primary essential hypertension. Poster presented at: 158th American Psychiatric Association Annual Meeting; May 21–26, 2005; Atlanta, GA.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed